Supreme Court Issues Temporary Stay Allowing Abortion Pill by Mail Until May 11
The U.S. Supreme Court has temporarily blocked a ruling by the Fifth Circuit Court of Appeals that sought to ban the distribution of the abortion pill Mifepristone by mail. This stay, effective immediately, preserves access to medication abortion nationwide until at least Monday, May 11, as the court weighs further action on the matter.
The stay means women across the country can continue to obtain Mifepristone via telemedicine and mail-order pharmacies without interruption for the next several days. The move comes amid growing uncertainty following the Fifth Circuit’s decision, which challenged FDA-approved protocols established to expand access to the medication.
Oregon Leads Coalition Challenging Ban to Protect Abortion Access
Oregon Attorney General Dan Rayfield joined a coalition of 21 states plus the District of Columbia in filing an application to the Supreme Court to overturn the Fifth Circuit’s ruling. Rayfield called Mifepristone “a safe, FDA-approved drug” that has been used by millions for decades, emphasizing the ruling lacked scientific and legal basis.
“Mifepristone is a safe, FDA-approved drug, and has been used by millions of people across our country for decades,” said Rayfield.
The coalition warned that restricting mail delivery would create chaos in reproductive healthcare nationwide, disproportionately harming rural and low-income communities dependent on telemedicine and mail services.
FDA and Medical Studies Affirm Safety of Mail-Delivered Abortion Pill
Initially, federal rules required women to obtain Mifepristone through in-person doctor visits. However, in 2026 the FDA revised these restrictions after extensive research showed medication abortion could be safely administered at home without direct supervision.
This regulatory update allowed certified pharmacies to distribute Mifepristone via mail, greatly improving access—especially in hard-to-reach regions. In Oregon alone, telemedicine abortions surged from 5% in 2022 to an estimated 27% in 2026. Nationally, medication abortions now represent nearly 63% of all abortions, with one in four conducted through telehealth.
What Happens Next
The Supreme Court will review arguments before the current stay expires on May 11. Meanwhile, patients in North Carolina and across the U.S. remain able to access medication abortion through existing telehealth and mail delivery channels without disruption.
Legal experts caution the temporary nature of this reprieve means the fight over access to medication abortion remains intensely active. The ruling and its challenge highlight an ongoing national battle over reproductive rights, with significant implications for healthcare access, particularly in conservative jurisdictions.
The NC Voice will continue to monitor this rapidly evolving story and provide updates on any court developments and state responses.
